French study simplifies chemotherapy for cancer patients

French study simplifies chemotherapy for cancer patients

French study simplifies chemotherapy for cancer patients
French study simplifies chemotherapy for cancer patients

A French study opened the way for a protocol that makes chemotherapy for cancer patients simpler by using subcutaneous injections instead of intravenous injections that are currently used, if this method proves effective in humans after testing on animals.

Cancer treatment is often based on intravenous chemotherapy, which generates many health consequences and requires hospitalization for the patient.

 However, a study conducted in France on animals and published by the American Chemical Society gave hope to make the procedure more simplified.

But resorting to this method, which is easier to implement and less inconvenience to the patient, is not possible in most cases because the active components of the treatment tend to stagnate in the subcutaneous tissues, causing necrosis due to its high toxicity.

Scientists have come up with a new approach that aims to overcome this obstacle by attaching the low soluble active ingredient, paclitaxel, which is widely used in chemotherapy, to a polymer that is highly hydrophobic.

This made it possible to create a soluble anticancer drug that could pass quickly from the subcutaneous tissue into the bloodstream without causing toxicity at the site of injection.

During preclinical trials of this new chemotherapy in mice, the scientists found that it was more effective than the commercial formulation of the active ingredient Taxol given intravenously.

Chemotherapy has many logistical requirements, such as providing qualified staff, hospitalization and other things, and a high cost, said the lead author of the study, director of research at the French National Center for Scientific Research (CNRS), Julien Nicolas, in a statement to AFP.

He stressed that the main benefit of this new approach lies in facilitating chemotherapy and enhancing the comfort of patients who may be able to receive treatment in their homes.

Although this research yielded promising results on an animal model, it has not yet been proven effective in humans, which prompted scientists to establish the startup "Imescia", and they hope to start clinical trials in 2024.

Why is a hysterectomy and what are the complications that can occur?

Post a Comment

* Please Don't Spam Here. All the Comments are Reviewed by Admin.

#buttons=(Accept !) #days=(30)

Our website uses cookies to enhance your experience. Learn More
Accept !